Gilead Sciences, Inc.
Data from Pivotal Phase III Studies of Gilead's Letairis ambrisentan for Pulmonary Arterial Hypertension WHO Group 1 in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Published in AIDS Weekly, June 9th, 2008
Gilead Sciences, Inc. (Nasdaq:GILD) announced that data from the pivotal Phase III ARIES-1 and ARIES-2 studies of Letairis(R) were published in Circulation online before print. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated as a once-daily treatment for pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional class II or III symptoms to improve exercise capacity and delay clinical worsening.
"This publication highlights the efficacy and safety observed in pivotal studies of ambrisentan, a treatment option for people living with PAH," said Professor Nazzareno Galie, Professor of Cardiology and Head of the Pulmonary Hypertension...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-06-09)
More Articles from AIDS Weekly
- Emory University
Protein that provides innate defense against HIV could lead to new treatments - Rockefeller University
Scientists image a single HIV particle being born - Antiretrovirals
Study results from E.M. Yakiwchuk and colleagues update understanding of antiretrovirals - HIV/AIDS
Bavarian Nordic Enters Clinical Trials With HIV Multiantigen Vaccine - HIV/AIDS
New cystic fibrosis findings from University of Munich described - HIV/AIDS
New HIV/AIDS study findings recently were reported by researchers at University of Texas - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
